Drug Profile
MP 20X
Alternative Names: MP-20XLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Medipure Holdings
- Class Anxiolytics; Cannabinoids
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Anxiety-disorders in Canada (Sublingual)
- 16 Jun 2015 Medipure Pharmaceuticals files for patent protection with US Patent and Trademark Office for MP 20X in USA
- 17 Feb 2015 Pilot clinical trials in Anxiety disorders in Canada (Sublingual)